Expanded Access for Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia

NCT00552500 ·Status: COMPLETED ·Phase: NA

Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

NCT05193578 ·Status: COMPLETED ·Phase: PHASE2

Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

NCT01231074 ·Status: COMPLETED ·Phase: PHASE1

Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage

NCT01783717 ·Status: UNKNOWN ·Phase: NA

The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity

NCT01384279 ·Status: COMPLETED ·Phase: NA

Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

NCT00617058 ·Status: TERMINATED ·Phase: PHASE2

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

NCT07138274 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Effects of Metyrapone in Patients With Hypercortisolism

NCT05255900 ·Status: COMPLETED

Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)

NCT01825798 ·Status: COMPLETED ·Phase: PHASE3

Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities

NCT02751307 ·Status: COMPLETED ·Phase: PHASE4

Dopamine Action on Metabolism in Relation to Genotype

NCT03525002 ·Status: COMPLETED ·Phase: PHASE2

Metformin for Weight Loss in Schizophrenia

NCT01177709 ·Status: TERMINATED ·Phase: NA

The Role of Apathy in Glycemic Control

NCT00844090 ·Status: COMPLETED ·Phase: NA

Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

NCT03817840 ·Status: COMPLETED

The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)

NCT00816907 ·Status: COMPLETED ·Phase: PHASE4

To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.

NCT00426608 ·Status: COMPLETED ·Phase: PHASE1

Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health

NCT05492305 ·Status: UNKNOWN

Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection

NCT06701838 ·Status: NOT_YET_RECRUITING

Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake

NCT06556277 ·Status: COMPLETED ·Phase: NA

Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment

NCT00699530 ·Status: WITHDRAWN

Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth

NCT00617240 ·Status: COMPLETED ·Phase: PHASE2

Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue

NCT01794429 ·Status: COMPLETED ·Phase: PHASE3

Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability

NCT05744479 ·Status: RECRUITING ·Phase: PHASE4

Determining Metabolic Effects of Valproate and Antipsychotic Therapy

NCT00167934 ·Status: COMPLETED ·Phase: NA

Metformin for Treatment of Antipsychotic-induced Dyslipidemia

NCT01778244 ·Status: COMPLETED ·Phase: PHASE4